Cell Therapy Liaison Meeting. Carl June, M.D.
|
|
- Merilyn Arnold
- 5 years ago
- Views:
Transcription
1 Cell Therapy Liaison Meeting Personalized Medicine Carl June, M.D. Professor of Pathology and Lab Medicine Abramson Cancer Center University of Pennsylvania October 17, 2008 AABB Headquarters Bethesda, MD
2 Overview: Adoptive T Cell Therapy Enable vaccination in immunosuppressed patients Reconstitute fludarabine induced immunodeficiency Therapy of progressive multifocal leukoencephalopathy (PML)
3 Hematologic Malignancies: Treatment Related Immunodeficiency Cytotoxic therapies cause severe and persistent immuodeficiencies and lymphopenia Immune reconstitution after hematopoietic stem cell transplant (HSCT) characterized by: Rapid (1-2 months) recovery of B cells Impaired T lymphocyte recovery (CD4 > CD8) Sustained antibody levels post-hsct require recovery of competent T cells Review of qualitative and quantitative aspects of immune recovery after auto PBSCT: Gauillame et al, Blood 92, 1471, 1998 Older patients have poor response to chemotherpy: more toxicity with FCR. Immune reconstitution important?
4 Treatment Related Immunodeficiency: Consequences Opportunistic infections Varicella, etc. Vaccine responses poor or absent ASBMT/CDC guideleines (Dykewicz, MMWR, 2000) Even when immunization is delayed until 12 months, antibody responses to capsular polysaccharide vaccines are poor and are unlikely to prevent disease -Only 19% of all enrolled patients developed protective antibody concentrations after the 24-month immunization (Guinan et al, 1994) Implications for tumor vaccines Prolonged lymphopenia may have implications for increased risk of relapse The worst: Progressive Multifocal Leukoencephalopathy
5 Prognostic Implications of Early Lymphocyte Recovery Post PBSCT for NHL Overall Survival NHL after PBSCT (104 patients) ALC recovery by day 15 Months Porrata et al. Blood 2001; 98: 579
6 General Approaches for Adoptive T Cell Therapy J Clin Invest :
7 Cell Culture Approaches for Adoptive T Cell Therapy
8 Clinical Scale T Cell Culture Process Total manufacturing costs: $15,650 Levine et al. Science. 1996; 272:1939 Levine et al. J Hematotherapy 1998: 7:437 Wave Bioreactors
9 Cell Manufacturing Flow Chart -Fresh Final Product Lymphocyte Apheresis $1,425 Day 0 Cryopreservation Thaw + CytoMate Wash $204 CD3/28 Positive Selection (SOP 0226) $1,161 Day 3 Day 5 Stimulation with CD3/CD28 Beads and Seed Culture in Baxter Lifecell Flasks D3 Pre-H: Maintain Culture in Baxter Lifecell Flasks D5 Load and Culture in Wave Bioreactor $922 $4,986 Remove Beads MaxSep Day 11 or Harvest Day Harvest Fenwal QC Testing and QA release Fresh Infusible Product $625 $3,400 Other costs: Labor, Equipment maintenance contracts, environmental monitoring, facility fees ~$4,600
10 Multiple Myeloma Plasma cell neoplasm characterized by serum monoclonal Ab, osteolytic lesions, pathological fractures, anemia, hypercalcemia 15% of hematologic malignancies Autologous transplants are highly effective for tumor reduction (first line therapy), but cures are infrequent. GVM/GVT: Allogeneic transplants can induce cures, but treatment-related risks are high.
11 Myeloma Phase I/II Adoptive Transfer Trials T Cell In Vitro Activation and Expansion to Infuse Cells Randomize Pneumococcal Vaccine (PCV) T Cell Collection Mobilization Stem Cell Collection High-dose Melphalan Stem Cell Transplant T Cell Infusion (Day +12 or +2) PCV vaccinations (Days +14, +42, +90) Study Day Rapoport et al. Nat. Med. 2005; 11: 1230 Immune Assessment Studies 100
12 CD3/28 Stimulated T Cell Infusion Leads to Rapid Lymphocyte Recovery Lymphocyte Count (per mm3) 5,000 4,000 3,000 2,000 1,000 T cell infusion CD3/28 T cells n = patients Controls (n=23-27) First successful randomized adoptive transfer trial Day of Transplant Gp 1+3 N=17 P = Gp 2+4 N=16
13 CD3/28 Stimulated T Cell Infusion Boosts Protective Antibody Levels Prevnar vaccines Pneumococcal IgG (mcg/ml) Gp 1,2 only T Cells Gp 1,3 T Cells Gp 1,3 T Cells Gp 2,4 T Cells Gp 2,4 Group 1 Group 2 Group 3 Group Days Group 1 vs other groups days 42 to 180: P<0.01
14 Adoptive transfer of vaccine primed T cells augments immunity in lymphodepleted hosts o First successful randomized multicenter adoptive immunotherapy trial: feasibility! o Accelerated recovery of CD4 and CD8 counts to normal levels by day 42 (P=0.004) o Protective antibody levels established by day 30 o Adoptive transfer of vaccine primed T cells appears to facilitate establishment of CD4 T central memory cells o Ongoing trial demonstrates striking schedule dependent effects of T cell transfer: day 2 vs day 12 post busulfan. Rapoport et al. Nat. Med. 2005; 11: 1230
15 UPCC 05402: Fludarabine-Cyclophosphamide With Immune System Support Using Costimulated Autologous T-cells in Patients With Previously Treated Relapsed/Refractory Follicular Lymphoma Rationale for phase I trial: (1) Prolonged lymphopenia and risk of opportunistic infections after fludarabine (2) Could Treg depletion tip the balance to increased effector function (i.e. less anergy) CD10 DR bcl-2 CD19 sig t(14;18) CD20 CD22 CD80 bcl-2 PI: Steven Schuster, M.D.
16 Effect of Fludarabine on T Cells Keating MJ, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92: , 1998
17 Follicular Lymphoma Study Design Relapsed / refractory FL (grade 1 or 2) Staging / PBL studies / apheresis Cryopreserve CF x 4-6 cycles Thaw / Monodeplete / CD25 Deplete Response Assessment / PBL Studies CR / CRu / PR / SD Co-stimulate and Expand In Vitro T-Cell Infusion (Day 0) Harvest PBL Studies / DTH Testing (Day 60) Response Assessment (Day 120) Anti-CD25 coated Epoxy beads Follow - up
18 Protocol Treatment CHEMOTHERAPY cyclophosphamide (250 mg/m2) days 1 3 fludarabine (25 mg/m2) days 1 3 T - CELL INFUSION DOSE LEVELS 1 - <5 x 10 9 CD3 + cells > 5-10 x 10 9 CD3 + cells
19 Subject Characteristics n = 13 Median age (years) 49 (range: 32 68) Sex (male : female) 5 : 8 Median number of prior therapies 2 (range: 1 3) Rituximab refractory 12 (92%) Stage II, II X, III, IV 1 (7.5%), 1 (7.5%), 7 (54%), 4 (31%) Bone marrow involved 1 (7.5%) Elevated LDH 2 (15%)
20 Enrollment and Results 13 subjects enrolled between May 2003 and March subjects removed after 2 CF cycles due hematologic toxicity; 1 subject removed after 4 CF cycles because of disease progression. 10 subjects received 4 CF cycles: 10 CD25-depleted, CD3/CD28-costimulated T-cell products generated: fold CD3 + cell expansion: median 26 (range 6 79) 10 T-cell products infused after 4 CF cycles: x 10 9 CD3+ cells x 10 9 CD3+ cells
21 Increase in T-Cell T Counts by Dose Level CD8 cells CD4 cells <5x10e9 >5x10e9 Dose Level median Day 30 T cell counts <5x10e9 >5x10e9 Dose Level p = (Wilcoxon signed-rank test)
22 Total CD4 and CD8 Counts over Time 700 n = T cell infusion cells / ul median CD4 median CD Pre-Rx month Long term correction of lymphopenia
23 Progressive Multifocal Leukoencephalopathy (PML) First described in 1958 in 2 CLL Pts, 1 HD Pt multiple CNS demyelinating lesions, rapid, fatal outcome Caused by ubiquitous polyoma virus, JC 35 cases reported post rituximab for lymphoma at Lugano. 32 died within 1 year. Occurs in up to 5% of AIDS Pts Before HAART, 1yr survival in HIV+ was 10% Natalizumab- humanized mab vs α4 integrin
24 T cells Transfer for Progressive Multifocal Leukocephalopathy (PML) 61 yo M w/cll since 1996 Previous therapy fludarabine, rituxan, cytoxan Relapsed /2007- Brain lesions may be Progressive Multifocal Leukoencephalopathy. Progressed on MRI in November Blood received 12/17/07 for pre-clinical evaluation of compassionate use T cell infusion Compassionate use IND
25 Case Report: Therapy of iatrogenic PML in CLL 10/23/07 11/3/07 Courtesy Igor BID
26 Gated FS/SS, then Viaprobe neg, CD19 neg, CD8 pos PBMC 12/17/ D0-PBMC D0-PBMC D0-PBMC % <0.02% <0.02% CEF JCV p36 JCV p100 Final Product: Expanded T-cells G1-PRE-H G1-PRE-H G1-PRE-H % 0.06% 0.05% CEF JCV p36 JCV p100 JCV p36, p100 courtesy Igor BID
27 PBMC 12/17/ D0-PBMC D0-PBMC D0-PBMC % <0.02% <0.02% PBMC , 7 days post-infusion PBMC PBMC PBMC % 0.09% 0.26% PBMC , 13 days post-infusion PBMC PBMC PBMC % 0.26% 0.20% PBMC , 27* days post-infusion PBMC PBMC PBMC % 0.08% 0.04% CEF JCV p36 JCV p100
28 Pt Current Status and next steps CD4/CD8 ratio increased from 0.5 to 1 after infusion Candida DTH, originally negative, now marginally positive (3mm) MRI: stable to improved 10 months post infusion. CLL stable disease Ongoing: longitudinal eval of JCV Large T Ag response, Treg levels
29 Points for Discussion Adoptive transfer of autologous costimulation leads to long term immune reconstitution in 1) myeloma; 2) follicular lymphoma/cll and 3) PML Clinical trial costs can not be supported with grants PML is orphan disease, nearly uniformly fatal in non- HIV setting Lack of biotechnology industry for T cell based therapies to facilitate technology transfer and enable wide availability. Personalized medicine requires randomized efficacy data. How to get there?
30 Collaborators and Acknowledgements U. Penn Bruce Levine Ed Stadtmauer Steve Schuster David Porter Richard Carroll Nicole Aqui Robert Vonderheide Elena Perez Carmine Carpenito Michael Milone Jim Riley U. Maryland Aaron Rapoport Alan Cross Dean Mann Robert Edelman Support NIH NCI Leukemia & Lymphoma Society
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationAdoptive transfer strategies: impacting Tregs and vaccines. Carl June, M.D. Personalized Medicine
Adoptive transfer strategies: impacting Tregs and vaccines Personalized Medicine isbtc Oncology Biologics Development Primer Carl June, M.D. Professor of Pathology and Lab Medicine Abramson Cancer Center
More informationCarl June, M.D. Personalized Medicine. Professor of Pathology and Lab Medicine Abramson Cancer Center University of Pennsylvania.
Challenges in the codevelopment of cell and biologic cancer therapies: Perspectives from academia Personalized Medicine Carl June, M.D. Professor of Pathology and Lab Medicine Abramson Cancer Center University
More informationChimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma
Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Stephen J. Schuster, M.D. Director, Lymphoma Program & Lymphoma Translational Research, Abramson Cancer
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationRiposta immune versus stato immune
Riposta immune versus stato immune Russell E. Lewis U.O. Malattie Infettive, Policlinico S. Orsola-Malpighi Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum Università di Bologna Immunodeficiency
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationRituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting
1 Recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Conditions: Waldenstrom's ; Waldenstrom Macroglobulinaemia Intervention: Biological: Ofatumumab Sponsor: GlaxoSmithKline Number
More informationBoost your immunotherapeutic research
Cell Isolation and Expansion Boost your immunotherapeutic research Dynabeads ClinExVivo CD3/CD28 Dynabeads CD3/CD28 Cell Isolation and Expansion Dynabeads ClinExVivo CD3/CD28 Isolate, activate, and expand
More informationBR for previously untreated or relapsed CLL
1 Protocol synopsis Title Rationale Study Objectives Multicentre phase II trial of bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationYescarta (axicabtagene ciloleucel)
Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationT-Receptor Modified Immune Therapy is Better Than Conventional DLI
T-Receptor Modified Immune Therapy is Better Than Conventional DLI David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center COSTEM, Berlin 10/13/13 Relapse After Allogeneic SCT:
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Chandran SS, Somerville RPT, Yang JC, et al.
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationDonor derived CD19 specific CAR + T cell therapy after haploidentical hematopoietic stem cell transplantation Laurence J.N. Cooper Hyatt Orlando
Donor derived CD19 specific CAR + T cell therapy after haploidentical hematopoietic stem cell transplantation Laurence J.N. Cooper Hyatt Orlando International Airport Hotel December 3, 2015 (afternoon)
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationProgressive Multifocal Leukoencephalopathy (PML)
Progressive Multifocal Leukoencephalopathy (PML) By Jamie Meier Introduction: Progressive multifocal leukoencephalopathy (PML) occurs when change in an individual s immune status triggers reactivation
More informationNEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)
NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationArzerra. Arzerra (ofatumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.03 Subject: Arzerra Page: 1 of 5 Last Review Date: June 22, 2017 Arzerra Description Arzerra (ofatumumab)
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationImmunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy
Immunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy This transcript has been edited for style and clarity and includes all slides from the presentation. This
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationTYSABRI Treatment Initiation Form
TYSABRI Treatment Initiation Form This form should be read carefully before starting treatment with TYSABRI. Please follow the advice in this form to ensure that you are fully informed of, and understand
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationPrecision CAR T Cell Therapeutics. Carl June October 15, 2018
Precision CAR T Cell Therapeutics Carl June October 15, 2018 Disclosure Information Carl June I have the following financial relationships to disclose: Consultant for: Novartis, Immune Design, Viracta,
More informationEngineering Artificial Antigen Presenting Cells for Efficient Expansion of T Cell Subsets
Engineering Artificial Antigen Presenting Cells for Efficient Expansion of T Cell Subsets Bruce Levine, Ph.D. Division of Transfusion Medicine Department of Pathology and Laboratory Medicine Abramson Cancer
More informationBACKGROUND AND RATIONALE
SYNOPSIS Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)
More informationMobilization & Pre-Transplant Conditioning Regimens
Transplant Process & Pre-Transplant Conditioning Regimens (auto patients only) 30 days before BMT (allo donors) 5 days before BMT Conditioning (auto AND allo patients) Transplant A technique used to increase
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationIl Rituximab nella ITP
Il Rituximab nella ITP Monica Carpenedo U.O.C Ematologia e TMO, Ospedale San Gerardo, Monza Burning questions about Rituximab and ITP What is the mechanism of action? What is long term effect of treatment?
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationClinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date:
Clinical Policy: (Zydelig) Reference Number: ERX.SPA.269 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More information7 Recruiting Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia
1 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom and Related Disorders Conditions: Multiple Myeloma; Waldenstrom's ; Smoldering Multiple Myeloma; Lymphoblastic Lymphoma Intervention:
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationChildren s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant
Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179
More informationStem Cell Sources 2/22/13. Cellular Therapy Today and Tomorrow. Cellular Therapy in HCT. Bone Marrow
2/22/13 Cellular Therapy Today and Tomorrow Robert S. Negrin, MD Division Chief, Stanford Bone and Marrow Transplant Program Professor of Medicine Cellular Therapy in Clinical Medicine Established Hematopoietic
More information12/22/2017 Patient education: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics) - UpToDate
Official reprint from UpToDate www.uptodate.com 2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved. The content on the UpToDate website is not intended nor recommended as a substitute for medical
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY ADCETRIS (Brentuximab Vedotin) MP-035-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Medical Management Annual
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationThe relationship between PML-rituximab and other immunobiologicals: an overview
The relationship between PML-rituximab and other immunobiologicals: an overview Renaud Du Pasquier, M.D. Associate professor in Neurology Neuroimmunology University Hospital of Vaud, Switzerland Transatlantic
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationLa Terapia Cellulare nella PML
Update sulle Malattie Infiammatorie e Infettive del SNC Pavia, 25 maggio 218 La Terapia Cellulare nella PML Sabrina Basso Oncoematologia Pediatrica Fondazione IRCCS Policlinico S. Matteo, Pavia Polyomavirus
More informationVaccines in Immunocompromised hosts
Vaccines in Immunocompromised hosts Carlos del Rio, MD Emory Center for AIDS Research October 2013 Immunocompromised hosts Number has increased rapidly in the past decades Broad term that encompasses different
More informationChildren s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant
Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More information